Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome: Results from MOR-004, a Phase III Trial

Clinical Therapeutics

Volumn 37, Issue 5, 2015, Pages 1012-1021.e6

  Schweighardt, Becky ^a   Tompkins, Troy ^a   Lau, Kelly ^a   Jesaitis, Lynne ^a   Qi, Yulan ^a   Musson, Donald G ^a   Farmer, Pamela ^a   Haller, Christine ^a   Shaywitz, Adam J ^a   Yang, Ke ^a   O'Neill, Charles A ^a  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

antibody; efficacy; enzyme replacement therapy; immunogenicity; Morquio A; mucopolysaccharidosis IVA

Indexed keywords

DRUG ANTIBODY; ELOSULFASE ALFA; IMMUNOGLOBULIN E; KERATAN SULFATE; NEUTRALIZING ANTIBODY; SOMATOMEDIN B RECEPTOR; GALNS PROTEIN, HUMAN; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

6 MINUTE WALK TEST; ADOLESCENT; ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; EXERCISE TEST; FEMALE; HUMAN; IMMUNOGENICITY; LYSOSOME; MAJOR CLINICAL STUDY; MALE; MORQUIO SYNDROME; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS IV; MULTICENTER STUDY; PRESCHOOL CHILD; PROCEDURES; URINE;

ANTIBODIES, NEUTRALIZING; CHILD; CHILD, PRESCHOOL; CHONDROITINSULFATASES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; ENZYME REPLACEMENT THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN E; KERATAN SULFATE; MALE; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS IV; RECOMBINANT PROTEINS;

EID: 84930275102     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.11.005     Document Type: Article

References (18)

1. C.J. Hendriksz, P. Harmatz, and M. Beck, et al. Review of clinical presentation and diagnosis of Mucopolysaccharidosis IVA Mol Genet Metab 110 2013 54 64
2. J. Nelson Incidence of the mucopolysaccharidoses in Northern Ireland Hum Genet 101 1997 355 358
3. J. Nelson, J. Crowhurst, B. Carey, and L. Greed Incidence of the mucopolysaccharidoses in Western Australia Am J Med Genet A 123A 2003 310 313
4. E. Yasuda, K. Fushimi, and Y. Suzuki, et al. Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder Mol Genet Metab 109 2013 301 311
5. P. Harmatz, K.E. Mengel, and R. Giugliani, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects Mol Genet Metab 109 2013 54 61
6. C.J. Hendriksz, C. Lavery, and M. Coker, et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey Orphanet J Rare Dis 9 2014 32 1172-9-32
7. M. Dvorak-Ewell, D. Wendt, and C. Hague, et al. Enzyme replacement in a human model of Mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice PLoS One 5 2010 e12194
8. D.A. Brooks, R. Kakavanos, and J.J. Hopwood Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder Trends Mol Med 9 2003 450 453
9. R.J. Desnick, and E.H. Schuchman Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges Annu Rev Genomics Hum Genet 13 2012 307 335
10. S.G. Banugaria, S.N. Prater, and Y.K. Ng The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease Genet Med 13 2011 729 736
11. Hendriksz CJ, Burton BK, Fleming TR. et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A Syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014; May 9 [Epub ahead of print].
12. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 166 2002 111 117
13. T.C. Wood, K. Harvey, and M. Beck, et al. Diagnosing mucopolysaccharidosis IVA J Inherit Metab Dis 36 2013 293 307
14. H.A. Sampson, A. Munoz-Furlong, and R.L. Campbell, et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium J Allergy Clin Immunol 117 2006 391 397
15. Y. Qi, D.G. Musson, and B. Schweighardt, et al. Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome Clin Pharmacokinet 2014
16. B. Benichou, S. Goyal, and C. Sung, et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease Mol Genet Metab 96 2009 4 12
17. M.M. Brands, M. Hoogeveen-Westerveld, and M.A. Kroos, et al. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase Orphanet J Rare Dis 8 2013 51
18. E. Jameson, S. Jones, and J.E. Wraith Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I Cochrane Database Syst Rev 9 2013 CD009354